Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors
These findings provide compelling evidence linking ICI therapy to the development of FT1DM, underscoring the need for clinical vigilance and early intervention strategies to optimize patient outcomes while leveraging the remarkable therapeutic potential of cancer immunotherapy.
Authors
- Yaochen Huang (ORCID: https://orcid.org/0000-0002-0558-7256)
- Shengling Fu
- Kelin Meng
- Wei Chen (ORCID: https://orcid.org/0000-0003-3348-4710)
- Wen‐Bin Zou
Institutions
- Union Hospital (HK)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1080/14740338.2024.2446422
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China